
Next week, I will be speaking at a very special “unconference” produced by Shwen Gwee of Vertex, titled “Social Pharmer - Sowing the Seeds of Social Media in Pharma and Healthcare.” I will be joined by some wonderful people and speakers, including Mark Senak, Steve Woodruff, Jack Barrette and Josh Bernoff.
The topic of my talk will be “Achieving Openness - Transparency and Authenticity in Pharma.” My talk will be the first session of the day and will focus on themes I’m sure we’ll be discussing throughout the day.
Most of the talks I’ve given have been pretty standard affairs. Normally, I make some remarks and take questions from the audience afterward. The unconference format is a bit different, as we are focusing on engaging as many people as possible in conversation and dialogue. As a result, I’d like to incorporate your comments and suggestions into my talk. I plan to work on my presentation late this week (and likely over the weekend), so you have a few days to get back to me with your thoughts. There are several issues I’d like to cover in my talk. Your answers will help ensure I’m hitting all of the right angles. They are:
-What should a truly open pharmaceutical company look like?
-How transparent should we expect pharmaceutical companies to be?
-Is it possible for a pharmaceutical company to be agile and flexible enough to truly engage people using social media in an open and transparent way?
-Is waiting for the FDA to develop social media marketing guidance like “Waiting for Godot?” What steps should pharmaceutical companies be taking individually and collectively to move the needle forward on developing standards of behavior and activity using social media? (See John Mack’s recent podcast on this issue for more information).
-What should true believers within pharmaceutical companies be doing to help their peers become psychologically prepared to engage in activities that may not bear fruit for a long period of time?
-How can we move from experimentation to true integration of social media technologies into the DNA of pharmaceutical companies?
-Should pharma marketers be thinking about corporate reputation even if they are engaging in activities on behalf of a particular product?
-What should pharma learn from others in the health industry who have embraced social media technologies about openness, responsiveness and transparency?
That’s all I have for now. I’m eagerly awaiting your comments and suggestions.
Comments as requested on twitter -
Too much flowery language and jargon. For instance- like “Waiting for Godot?” - too esoteric. "bear fruit"
Would try to simplify and clarify. Don't make ppl guess about your point.
my $.02
Posted by: Anonymous | April 16, 2009 1:25 PM | Permalink to Comment